Abstract
Bioject Medical Technologies Inc. Market Share Analysis
Summary
GlobalData’s new report, “Bioject Medical Technologies Inc. Market Share Analysis” provides in-depth information on Bioject Medical Technologies Inc.’s market position in the needle-free injections market. The report also provides data and information on the overall competitive landscape within the needle-free injections market. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
• Global company shares (in Revenues) information for the needle-free injections market.
• Bioject Medical Technologies Inc.’s company shares (in Revenues) information for all the key countries the company has presence in -Japan, China, Australia, United Kingdom, France, Germany, Spain, Italy, United States, Canada and Brazil.
• Bioject Medical Technologies Inc.’s company shares (in Revenues) information for the needle-free injections market.
• All the key data-points are for 2010 and cover all the key regions - North America, Middle East and Africa, Europe, Asia-Pacific and South and Central America.
• Global corporate-level profile with information on the company’s business segments, major products and services, competitors, and locations and subsidiaries.
• The company profile is also supplemented with a SWOT Analysis with in-depth information and analysis of the company’s value proposition and the business climate it operates in.
• Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any.
Reasons To Buy
• Develop sales and marketing strategies by identifying who-stands-where in the markets, Bioject Medical Technologies Inc.’s operates in.
• Plan your competition strategies by identifying the company’s shares in the markets and geographic regions it operates in.
• Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
• Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
• Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to Bioject Medical Technologies Inc.’s market positions.
Companies Mentioned
The following companies are the major competitors of Bioject Medical Technologies Inc.:
Antares Pharma, Inc.
Becton, Dickinson and Company
Consort Medical plc
INJEX - Equidyne Systems
Terumo Corporation
The Medical House PLC
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets/Categories Covered
3.1 Needle Free Injections
4 Company Snapshot
4.1 Key Information
4.2 Company Overview
4.3 Financial Performance
4.4 SWOT Snapshot
5 Business Description
5.1 Business Overview
5.2 Biojector 2000 Product Line
5.2.1 Overview
5.2.2 Financials
5.3 Spring Powered Product Line
5.3.1 Overview
5.3.2 Financials
5.4 Vial Adapters Product Line
5.4.1 Overview
5.4.2 Financials
5.5 Vial Adapters Product Line
5.5.1 Overview
5.5.2 Financials
5.6 Major Products and Services
5.6.1 Overview
6 History
7 Business Strategy
7.1 Mission Statement
8 SWOT Analysis
8.1 Overview
8.2 Bioject Medical Technologies Inc. Strengths
8.2.1 Strong Efficiency Ratios
8.2.2 Proprietary Needle-Free Injection Technology
8.2.3 Strong Research and Development
8.2.4 Strategic Alliances
8.3 Bioject Medical Technologies Inc. Weaknesses
8.3.1 Revenue Concentration
8.3.2 Declining Profitability
8.3.3 Decline in Liquidity Ratio’s
8.4 Bioject Medical Technologies Inc. Opportunities
8.4.1 Strong Pipeline Products
8.4.2 DNA-Based Preventative and Therapeutic Treatments
8.4.3 Global Drug Delivery Devices Market
8.4.4 Rising Healthcare Expenditure in the US
8.5 Bioject Medical Technologies Inc. Threats
8.5.1 Uncertain R&D Outcomes
8.5.2 Competitive Pressures
8.5.3 Rapid Technological Change
8.5.4 Stringent Government Regulations
9 Competitors
10 Competitive Landscape
10.1 Needle Free Injections, Global, Market Share (%), 2010
11 Bioject Medical Technologies Inc. Medical Equipment Market Share Analysis
11.1 Bioject Medical Technologies Inc., Needle Free Injections, Global, Market Share (2010)
11.2 Bioject Medical Technologies Inc., Asia-Pacific, Market Share (2010)
11.3 Bioject Medical Technologies Inc., Europe, Market Share (2010)
11.4 Bioject Medical Technologies Inc., Middle East and Africa, Market Share (2010)
11.5 Bioject Medical Technologies Inc., North America, Market Share (2010)
11.6 Bioject Medical Technologies Inc., South and Central America, Market Share (2010)
12 Share Holding Structure
13 Key Employees
14 Key Employee Biographies
15 Company Statement
16 Locations And Subsidiaries
16.1 Head Office
17 Financial Deals Landscape
17.1 Bioject Medical Technologies Inc., Deals Volume Summary, 2006 to YTD 2011
18 Bioject Medical Technologies Inc. Detailed Deal Summary
18.1 Partnerships
18.1.1 Bioject Medical Technologies Enters Into An Agreement With Vical
18.1.2 Bioject Medical Technologies Enters Into Research Collaboration With International AIDS Vaccine
18.1.3 Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies
18.2 Equity Offering
18.2.1 Bioject Medical Technologies Completes Private Placement Of Preferred Stock For $0.5 Million
18.2.2 Bioject Medical Technologies Completes Private Placement
18.2.3 Bioject Medical Technologies Completes Private Placement
18.2.4 Bioject Medical Completes Private Placement $1.21 Million
19 Recent Developments
19.1 Strategy And Business Planning
19.1.1 Jan 11, 2010: MPI Research Forms Strategic Alliance With Bioject
19.1.2 Oct 31, 2006: Bioject Expands Agreement With European Biotechnology Company
19.2 Financial Announcements
19.2.1 May 11, 2011: Bioject Reports Revenue Of $1.7m In Q1 2011
19.2.2 Mar 23, 2011: Bioject Reports Total Revenue Of $5.6m In 2010
19.2.3 Nov 10, 2010: Bioject Reports Revenues Of $1.52 Million For Q3 2010
19.2.4 Aug 04, 2010: Bioject Reports Net Loss Of $0.5 Million For Q2 2010
19.2.5 May 12, 2010: Bioject Reports Total Revenues Of $1.19 Million In Q1 2010
19.2.6 Mar 17, 2010: Bioject Reports Revenues Of $6.7 Million In 2009
19.2.7 Nov 04, 2009: Bioject Reports Revenues Of $1.5 Million In Q3 2009
19.2.8 Aug 05, 2009: Bioject Reports Revenues Of $1.67 Million In Q2 2009
19.2.9 May 06, 2009: Bioject Reports Revenues Of $1.9 Million In Q1 2009
19.2.10 Mar 25, 2009: Bioject Posts Net Loss Of $3.5 Million For 2008
19.2.11 Nov 10, 2008: Bioject Reports 3Q 2008 Results
19.2.12 Aug 06, 2008: Bioject Reports 2Q 2008 Results
19.2.13 May 07, 2008: Bioject Declares Q1 2008 Results
19.3 Corporate Communications
19.3.1 Jul 22, 2008: Bioject To Transfer From NASDAQ To OTCBB
19.3.2 Oct 02, 2007: Bioject Appoints New CEO
19.3.3 Oct 20, 2006: Bioject CEO To Retire
19.4 Product News
19.4.1 Sep 28, 2010: Bioject Announces Utilization Of Biojector 2000 In Study Sponsored By NIAID
19.4.2 Jul 08, 2010: Bioject Announces Use Of Its Intradermal Needle-Free Delivery System In World Health Organization Clinical Trial In Oman With Poliovirus Vaccine
19.4.3 Apr 04, 2009: Bioject Medical Technologies Receives US FDA Approval To Market Zetajet Needle-Free Injection Therapy System
19.4.4 Feb 24, 2009: Bioject Medical Announces Collaborative Research Agreement With IAVI
19.4.5 May 27, 2008: Biojector 2000 Technology Put To The Test In CDC Flu Vaccine Study
19.4.6 Dec 15, 2007: Bioject Announces Completion Of Phase I Study Comparing The Iject Pre- Filled, Needle-Free Drug Delivery System To Traditional Needle-And-Syringe
19.5 Other Significant Developments
19.5.1 Feb 24, 2009: Bioject Enters Supply Contract With IAVI
19.5.2 Feb 10, 2009: Bioject Extends Supply Contract With Ferring
19.5.3 Jun 23, 2008: Bioject Signs Agreement With Merial
19.5.4 Nov 07, 2006: Bioject Signs Agreement With Vical
20 Appendix
20.1 Research Methodology
20.2 Secondary Research
20.3 Primary Research
20.4 Models
20.5 Forecasts
20.6 Expert Panels
20.7 GlobalData Consulting
20.8 Currency Conversion
20.9 Contact Us
20.10 Disclaimer
List of Tables
1.1 List of Tables
Table 1: Bioject Medical Technologies Inc., Key Facts, 2010
Table 2: Bioject Medical Technologies Inc., SWOT Analysis, 2010
Table 3: Needle Free Injections, Global, Company Share by Revenue ($m), 2010
Table 4: Bioject Medical Technologies Inc, Needle Free Injections, Global, Revenue ($m) and Market Share (%), 2010
Table 5: Bioject Medical Technologies Inc, Needle Free Injections, Asia-Pacific, Revenue ($m) and Market Share (%), 2010
Table 6: Bioject Medical Technologies Inc, Needle Free Injections, Europe, Revenue ($m) and Market Share (%), 2010
Table 7: Bioject Medical Technologies Inc, Needle Free Injections, Middle East and Africa, Revenue ($m) and Market Share (%), 2010
Table 8: Bioject Medical Technologies Inc, Needle Free Injections, North America, Revenue ($m) and Market Share (%), 2010
Table 9: Bioject Medical Technologies Inc., Needle Free Injections, South and Central America, Revenue ($m) and Market Share (%), 2010
Table 10: Bioject Medical Technologies Inc., Share Holding Structure
Table 11: Bioject Medical Technologies Inc., Key Employees
Table 12: Bioject Medical Technologies Inc., Deals Volume Summary, 2006 to YTD 2011
Table 13: Bioject Medical Technologies Inc., Deals Summary, 2006 to YTD 2011
Table 14: Bioject Medical Technologies Enters Into An Agreement With Vical
Table 15: Bioject Medical Technologies Enters Into Research Collaboration With International AIDS Vaccine
Table 16: Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies
Table 17: Bioject Medical Technologies Completes Private Placement Of Preferred Stock For $0.5 Million
Table 18: Bioject Medical Technologies Completes Private Placement
Table 19: Bioject Medical Technologies Completes Private Placement
Table 20: Bioject Medical Completes Private Placement $1.21 Million
Table 21: USD to Local Currency, Average Exchange Rate, 2010
List of Figures
1.2 List of Figures
Figure 1: Needle Free Injections, Global, Market Share (%), 2010
Figure 2: Bioject Medical Technologies Inc, Needle Free Injections, Global, Market Share (%), 2010
Figure 3: Bioject Medical Technologies Inc, Needle Free Injections, Asia-Pacific, Market Share (%), 2010
Figure 4: Bioject Medical Technologies Inc, Needle Free Injections, Europe, Market Share (%), 2010
Figure 5: Bioject Medical Technologies Inc, Needle Free Injections, North America, Market Share (%), 2010
Figure 6: Bioject Medical Technologies Inc., Deals Volume Summary, 2006 to YTD 2011
